Norway's Arctic Bioscience 2025 revenue falls due to product recall impact

Arctic Bioscience AS

26/02/2026 06:13

Overview

Norway biotech firm's Q4 2025 revenue fell to NOK 13.9 mln due to 2024 recall impact

Company reduced operational costs significantly, improving adjusted EBITDA in 2025

Strong order intake for 2026 indicates growth opportunities in nutraceutical business

Outlook

Company expects strong growth in nutraceutical business for 2026

Arctic Bioscience plans to publish HeROPA trial data in 2026

Company closely monitors liquidity and assesses measures

Result Drivers

COST REDUCTION - Co implemented cost reduction initiatives in 2025, significantly lowering operational costs

PRODUCT RECALL IMPACT - 2025 revenue was negatively influenced by a product recall incident from late 2024

MARKET EXPANSION - Co expanded into Swedish B2C market and plans further European and Asian market growth

Company press release: ID:nWkr8XmX4j

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EBITDA
-NOK 6.90 mln
Q4 Gross Margin
22.70%
Q4 Gross Profit
NOK 3.20 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Arctic Bioscience AS is NOK2.50, about 26.9% below its February 25 closing price of NOK3.42

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)